3D SYSTEMS CORP, 10-Q filed on 8/11/2025
Quarterly Report
v3.25.2
Cover Page - shares
 6 Months Ended
Jun. 30, 2025
Aug. 04, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2025  
Document Transition Report false  
Entity File Number 001-34220  
Entity Registrant Name 3D SYSTEMS CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 95-4431352  
Entity Address, Address Line One 333 Three D Systems Circle  
Entity Address, City or Town Rock Hill  
Entity Address, State or Province SC  
Entity Address, Postal Zip Code 29730  
City Area Code 803  
Local Phone Number 326-3900  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol DDD  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   128,252,556
Amendment Flag false  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2025  
Current Fiscal Year End Date --12-31  
Entity Central Index Key 0000910638  
v3.25.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 116,358 $ 171,324
Accounts receivable, net of reserves — $3,723 and $2,433 97,113 101,471
Inventories 132,897 118,530
Prepaid expenses and other current assets 43,754 34,329
Assets held for sale 0 3,176
Total current assets 390,122 428,830
Property and equipment, net 51,279 51,044
Intangible assets, net 17,282 18,020
Goodwill 15,576 14,879
Operating lease right-of-use assets 50,257 50,715
Finance lease right-of-use assets 8,340 8,726
Long-term deferred income tax assets 3,319 2,063
Other assets 51,669 34,569
Total assets 587,844 608,846
Current liabilities:    
Current operating lease liabilities 11,909 9,514
Accounts payable 36,362 41,833
Accrued and other liabilities 53,641 45,488
Customer deposits 4,315 4,712
Deferred revenue 35,079 27,298
Liabilities held for sale 0 10,251
Total current liabilities 141,306 139,096
Long-term debt, net of deferred financing costs 122,643 211,995
Long-term operating lease liabilities 49,823 52,527
Long-term deferred income tax liabilities 3,361 2,076
Other liabilities 27,272 25,001
Total liabilities 344,405 430,695
Commitments and contingencies (Note 12)
Redeemable non-controlling interest 2,193 1,958
Stockholders’ equity:    
Common stock, $0.001 par value, authorized 220,000 shares; shares issued 127,987 and 135,510 as of June 30, 2025 and December 31, 2024, respectively 128 136
Additional paid-in capital 1,578,836 1,593,366
Accumulated deficit (1,294,793) (1,362,243)
Accumulated other comprehensive loss (42,925) (55,066)
Total stockholders’ equity 241,246 176,193
Total liabilities, redeemable non-controlling interest and stockholders’ equity $ 587,844 $ 608,846
v3.25.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for credit loss, current $ 3,723 $ 2,433
Stockholders’ equity:    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 220,000,000 220,000,000
Common stock, shares issued (in shares) 127,987,000 135,510,000
v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenue:        
Total revenue $ 94,838 $ 113,252 $ 189,378 $ 216,157
Cost of sales:        
Total cost of sales 58,688 66,154 120,539 128,137
Gross profit 36,150 47,098 68,839 88,020
Operating expenses:        
Selling, general and administrative 34,139 51,494 83,908 108,798
Research and development 17,361 22,016 37,044 45,496
Total operating expenses 51,500 73,510 120,952 154,294
Loss from operations (15,350) (26,412) (52,113) (66,274)
Non-operating income (loss):        
Foreign exchange gain (loss), net (1,591) (723) (452) 1,186
Interest income 1,717 1,452 2,670 4,250
Interest expense (697) (624) (1,278) (1,338)
Gain on disposition 125,681 0 125,681 0
Other income, net 7,020 384 6,860 21,770
Total non-operating income 132,130 489 133,481 25,868
Net income (loss) before income taxes 116,780 (25,923) 81,368 (40,406)
Provision for income taxes (11,018) (476) (11,689) (1,847)
Loss on equity method investments, net of income taxes (1,326) (902) (2,229) (1,149)
Net income (loss) before redeemable non-controlling interest 104,436 (27,301) 67,450 (43,402)
Less: net loss attributable to redeemable non-controlling interest 0 (43) 0 (143)
Net income (loss) attributable to 3D Systems Corporation $ 104,436 $ (27,258) $ 67,450 $ (43,259)
Net income (loss) per common share:        
Basic (in dollars per share) $ 0.79 $ (0.21) $ 0.51 $ (0.33)
Diluted (in dollars per share) $ 0.57 $ (0.21) $ 0.37 $ (0.33)
Weighted average shares outstanding:        
Basic (in shares) 132,280 131,802 132,370 131,311
Diluted (in shares) 182,716 131,802 183,237 131,311
Products        
Revenue:        
Total revenue $ 53,801 $ 71,733 $ 108,524 $ 135,784
Cost of sales:        
Total cost of sales 32,274 42,451 69,639 82,038
Services        
Revenue:        
Total revenue 41,037 41,519 80,854 80,373
Cost of sales:        
Total cost of sales $ 26,414 $ 23,703 $ 50,900 $ 46,099
v3.25.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Statement of Comprehensive Income [Abstract]        
Net income (loss) before redeemable non-controlling interest $ 104,436 $ (27,301) $ 67,450 $ (43,402)
Other comprehensive income (loss), net of taxes:        
Pension plan adjustments 14 (2) 20 (9)
Foreign currency translation 9,075 (1,196) 12,121 (8,382)
Total other comprehensive income (loss), net of taxes: 9,089 (1,198) 12,141 (8,391)
Total comprehensive income (loss), net of taxes 113,525 (28,499) 79,591 (51,793)
Less: comprehensive loss attributable to redeemable non-controlling interest 0 (43) 0 (143)
Comprehensive income (loss) attributable to 3D Systems Corporation $ 113,525 $ (28,456) $ 79,591 $ (51,650)
v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
OPERATING ACTIVITIES    
Net income (loss) before redeemable non-controlling interest $ 67,450 $ (43,402)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 10,907 14,772
Accretion of debt discount 652 749
Stock-based compensation 607 13,673
Non-cash operating lease expense 2,371 4,992
Provision for inventory obsolescence 2,130 6,165
Provision for bad debts 1,622 (25)
(Gain) loss on the disposition of businesses, property, equipment and other assets (125,825) 643
Gain on debt extinguishment (8,203) (21,518)
Provision (benefit) for deferred income taxes and reserve adjustments (3,124) 451
Loss on equity method investment, net of taxes 2,229 1,149
Changes in operating accounts:    
Accounts receivable 9,394 2,438
Inventories (11,137) 479
Prepaid expenses and other current assets (6,362) 149
Accounts payable (8,142) (7,387)
Deferred revenue and customer deposits 7,094 3,943
Accrued and other liabilities 5,009 (7,325)
All other operating activities (6,302) (6,254)
Net cash used in operating activities (59,630) (36,308)
INVESTING ACTIVITIES    
Purchases of property and equipment (5,743) (7,151)
Proceeds from sale of assets and businesses, net of cash sold 119,400 96
Acquisitions and other investments, net of cash acquired (900) (2,450)
Other investing activities 174 0
Net cash provided by (used in) investing activities 112,931 (9,505)
FINANCING ACTIVITIES    
Proceeds from borrowings 92,030 0
Debt issuance costs (3,425) 0
Repayment of borrowings and long-term debt (169,987) (87,218)
Stock repurchases (14,960) 0
Taxes paid related to net-share settlement of equity awards (605) (2,503)
Other financing activities (393) (659)
Net cash used in financing activities (97,340) (90,380)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 5,104 (2,632)
Net decrease in cash, cash equivalents and restricted cash (38,935) (138,825)
Cash, cash equivalents and restricted cash at the beginning of the year 172,883 333,111
Cash, cash equivalents and restricted cash at the end of the period 133,948 194,286
Balances per Condensed Consolidated Balance Sheets:    
Cash and cash equivalents 116,358 192,732
Restricted cash included in prepaid expenses and other current assets 125 121
Restricted cash included in other assets [1] 17,465 1,433
Total cash, cash equivalents and restricted cash 133,948 194,286
Supplemental cash flow information    
Lease assets obtained in exchange for new lease liabilities 42 997
Cash interest payments 239 512
Cash income tax payments, net 3,671 3,688
Transfer of equipment from inventory to property and equipment, net [2] 1,662 1,637
Exchange of assets for investment $ 1,016 $ 0
[1] The balance in restricted cash as of June 30, 2025 includes (1) $16.8 million of restricted cash for the remaining balance of the 2026 Notes for debt holders who participated in the June 2025 repurchase transaction. Refer to Note 6 for further information. (2) The remaining balance primarily relates to guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The balance in restricted cash as of June 30, 2024 primarily relates to guarantees in the form of a standby letter of credit as security for a long-term real estate lease. Refer to Note 12 for further information.
[2] Inventory is transferred to property and equipment at cost when we require additional machines for training or demonstration or for placement into on demand manufacturing services locations.
v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)
$ in Millions
Jun. 30, 2025
USD ($)
Statement of Cash Flows [Abstract]  
Restricted cash $ 16.8
v3.25.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2023   133,619      
Beginning balance at Dec. 31, 2023 $ 426,753 $ 134 $ 1,577,519 $ (1,106,650) $ (44,250)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued, vested and canceled under equity incentive plans (in shares)   534      
Shares withheld related to net-share settlement of equity awards (in shares)   (350)      
Shares withheld related to net-share settlement of equity awards (1,710)   (1,710)    
Stock-based compensation expense 6,591   6,591    
Net income (loss) attributable to 3D Systems Corp. (16,001)     (16,001)  
Pension plan adjustment (7)       (7)
Redeemable non-controlling interest redemption value in excess of carrying value (75)   (75)    
Foreign currency translation adjustment (7,186)       (7,186)
Ending balance (in shares) at Mar. 31, 2024   133,803      
Ending balance at Mar. 31, 2024 408,365 $ 134 1,582,325 (1,122,651) (51,443)
Beginning balance (in shares) at Dec. 31, 2023   133,619      
Beginning balance at Dec. 31, 2023 426,753 $ 134 1,577,519 (1,106,650) (44,250)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) attributable to 3D Systems Corp. (43,259)        
Redeemable non-controlling interest redemption value in excess of carrying value (173)        
Ending balance (in shares) at Jun. 30, 2024   133,587      
Ending balance at Jun. 30, 2024 381,729 $ 134 1,584,145 (1,149,909) (52,641)
Beginning balance (in shares) at Mar. 31, 2024   133,803      
Beginning balance at Mar. 31, 2024 408,365 $ 134 1,582,325 (1,122,651) (51,443)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued, vested and canceled under equity incentive plans (in shares)   8      
Shares withheld related to net-share settlement of equity awards (in shares)   (224)      
Shares withheld related to net-share settlement of equity awards (793)   (793)    
Stock-based compensation expense 2,711   2,711    
Net income (loss) attributable to 3D Systems Corp. (27,258)     (27,258)  
Pension plan adjustment (2)       (2)
Redeemable non-controlling interest redemption value in excess of carrying value (98)   (98)    
Foreign currency translation adjustment (1,196)       (1,196)
Ending balance (in shares) at Jun. 30, 2024   133,587      
Ending balance at Jun. 30, 2024 381,729 $ 134 1,584,145 (1,149,909) (52,641)
Beginning balance (in shares) at Dec. 31, 2024   135,510      
Beginning balance at Dec. 31, 2024 176,193 $ 136 1,593,366 (1,362,243) (55,066)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued, vested and canceled under equity incentive plans (in shares)   (53)      
Shares issued, vested and canceled under equity incentive plans (1) $ (1)      
Shares withheld related to net-share settlement of equity awards (in shares)   (96)      
Shares withheld related to net-share settlement of equity awards (285)   (285)    
Stock-based compensation expense 3,666   3,666    
Net income (loss) attributable to 3D Systems Corp. (36,986)     (36,986)  
Pension plan adjustment 6       6
Foreign currency translation adjustment 3,046       3,046
Ending balance (in shares) at Mar. 31, 2025   135,361      
Ending balance at Mar. 31, 2025 145,639 $ 135 1,596,747 (1,399,229) (52,014)
Beginning balance (in shares) at Dec. 31, 2024   135,510      
Beginning balance at Dec. 31, 2024 176,193 $ 136 1,593,366 (1,362,243) (55,066)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) attributable to 3D Systems Corp. 67,450        
Redeemable non-controlling interest redemption value in excess of carrying value 0        
Ending balance (in shares) at Jun. 30, 2025   127,987      
Ending balance at Jun. 30, 2025 241,246 $ 128 1,578,836 (1,294,793) (42,925)
Beginning balance (in shares) at Mar. 31, 2025   135,361      
Beginning balance at Mar. 31, 2025 145,639 $ 135 1,596,747 (1,399,229) (52,014)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued, vested and canceled under equity incentive plans (in shares)   784      
Shares issued, vested and canceled under equity incentive plans 1 $ 1      
Shares withheld related to net-share settlement of equity awards (in shares)   (158)      
Shares withheld related to net-share settlement of equity awards (320)   (320)    
Stock-based compensation expense (2,507)   (2,507)    
Net income (loss) attributable to 3D Systems Corp. 104,436     104,436  
Pension plan adjustment 14       14
Redeemable non-controlling interest redemption value in excess of carrying value 0        
Repurchase and retirements of common stock (in shares)   (8,000)      
Repurchase and retirements of common stock (14,960) $ (8) (14,952)    
Foreign currency translation adjustment 8,943   (132)   9,075
Ending balance (in shares) at Jun. 30, 2025   127,987      
Ending balance at Jun. 30, 2025 $ 241,246 $ 128 $ 1,578,836 $ (1,294,793) $ (42,925)
v3.25.2
BASIS OF PRESENTATION
 6 Months Ended
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
NOTE 1 - BASIS OF PRESENTATION
3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and Asia Pacific and Oceania (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions (which includes dental, medical devices, personalized health services and regenerative medicine) and Industrial Solutions (which includes aerospace, defense, transportation and general manufacturing). We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

Consolidated Entities
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all majority-owned and wholly-owned subsidiaries and entities in which a controlling interest is maintained. Intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current year presentation. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 ( the “2024 Annual Report on Form 10-K”). The Company believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading. In the opinion of management, the unaudited condensed consolidated financial statements contain all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the Company's financial position, results of operations, and cash flows for the periods presented. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions.
Our annual reporting period is the calendar year. The Company's results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the full year.

Summary of Significant Accounting Policies
There have been no significant changes to our accounting policies since those disclosed in the Company's 2024 Annual Report on Form 10-K.
Finance Leases
As of June 30, 2025 and December 31, 2024, short-term finance lease obligations of $1.6 million and $1.5 million, respectively, are included in Accrued and other liabilities, and long-term finance lease obligations of $10.1 million and $10.5 million, respectively, are included in Other liabilities on our Condensed Consolidated Balance Sheets.

Amortization of Intangible Assets
Amortization expense related to our intangible assets with finite lives was $0.6 million and $1.2 million for the three and six months ended June 30, 2025, respectively, and $2.1 million and $4.1 million for the three and six months ended June 30, 2024, respectively.
Goodwill
Based primarily on macroeconomic uncertainties, our updated strategic plans and restructuring initiatives and the decline in our stock price during the second quarter of 2025, we concluded that changes to the timing and amount of expected future cash flows, among other factors, indicated a triggering event requiring an interim goodwill impairment assessment of our Healthcare reporting unit. As a result of the quantitative interim impairment test performed in the second quarter of 2025, we concluded that there was no impairment, as the estimated fair value of the Healthcare reporting unit exceeded the carrying value.
To determine the fair value of the reporting unit, we performed our impairment test using a combination of an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 26.2%. The discount rate was based on the weighted average cost of capital, determined using market, and industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment.
While there was no impairment found during our interim goodwill impairment test in the second quarter of 2025, changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairments tests could affect the implied fair value of goodwill and may result in impairment charges in the future.
Recently Adopted Accounting Standards
In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments," related to induced conversions of convertible debt instruments. The amendments in this ASU clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions rather than as debt extinguishments. The Company early adopted this ASU as of April 1, 2025 and applied the guidance on a prospective basis. Adoption did not have a material impact on our condensed consolidated financial statements.

Recently Issued Accounting Standards Not Yet Adopted
In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, while permitted to be adopted on a retrospective basis. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Upon adoption, this ASU is expected to result in the inclusion of additional tax-related disclosures in the footnotes to our consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The amendments in this ASU require public entities to provide disaggregated disclosure of expenses included within relevant income statement expense captions, as well as additional disclosures about selling expenses. This update is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments in this ASU should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of the ASU or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is currently in the process of evaluating the effects of this ASU on our consolidated financial statements.
v3.25.2
REVENUES
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES
NOTE 2 - REVENUES

Contract Assets
In certain circumstances, contract assets are recorded to include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customers, and right to payment is subject to contractual performance obligations rather than subject only to the passage of time. Contract assets were $0.5 million and $0.3 million as of June 30, 2025 and December 31, 2024, respectively, and are included in Prepaid expenses and other current assets on the accompanying Condensed Consolidated Balance Sheets.

Contract Liabilities
Our contract liabilities consist of deferred revenue generally related to maintenance and service contracts, post-sale support and extended warranty sales, where we generally receive up-front payment and recognize revenue over the service or support term. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. The current portion of deferred revenue is recorded within Accrued and other liabilities and the non-current portion of deferred revenue is recorded within Other liabilities on our Condensed Consolidated Balance Sheets.
Our contract liabilities consisted of the following:
(in thousands)June 30, 2025December 31, 2024
Deferred revenue, current and customer deposits$39,394 $32,010 
Deferred revenue, noncurrent3,652 2,259 
Total contract liabilities$43,046 $34,269 
During the three and six months ended June 30, 2025, the Company recognized $11.1 million and $25.1 million, respectively, of revenue related to the Company's contract liabilities at December 31, 2024. The change in contract liabilities from December 31, 2024 to June 30, 2025 was primarily due to the timing of cash receipts and sales of extended service contracts.
Collaborative Arrangements
The Company enters into collaborative arrangements with customers that provide for cost reimbursement of certain expenses and potential milestone payments.
The Company recognized $3.6 million and $6.4 million in product revenue, and $1.3 million and $3.8 million in product cost of sales, related to collaborative arrangements during the three and six months ended June 30, 2025, respectively. For the three and six months ended June 30, 2024, the Company recognized $1.8 million and $3.8 million in product revenue and $1.3 million and $3.4 million in product cost of sales, respectively, related to collaborative arrangements.

Remaining Performance Obligations
Remaining performance obligations represent the transaction price allocated to performance obligations that are unsatisfied as of the end of the period. As of June 30, 2025, the Company had $6.4 million of remaining performance obligations, primarily related to maintenance and service contracts, post-sale support and extended warranties. We expect approximately 90% to be recognized as revenue within the next two years, and the remaining thereafter. We have excluded performance obligations with an original expected duration of one year or less.
Revenue Concentration
Revenue, by the geographic region in which a sale originated, was as follows:
Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Americas
$55,317 $66,179 $107,252 $126,784 
EMEA
33,140 37,537 66,575 71,437 
APAC6,381 9,536 15,551 17,936 
Total$94,838 $113,252 $189,378 $216,157 

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
United States (included within Americas)
$54,632 $65,432 $105,531 $125,325 
Germany (included within EMEA)
12,879 17,303 29,862 31,545 
For the three and six months ended June 30, 2025 one customer accounted for 9.7% and 10.8% of our consolidated revenue, respectively. For the three and six months ended June 30, 2024, one customer accounted for 16.0% and 16.1% of our consolidated revenue, respectively. We expect to maintain our relationship with this customer.
v3.25.2
INVENTORIES
 6 Months Ended
Jun. 30, 2025
Inventory Disclosure [Abstract]  
INVENTORIES
NOTE 3 - INVENTORIES

(in thousands)June 30, 2025December 31, 2024
Raw materials$46,659 $43,138 
Work in process2,954 3,481 
Finished goods and parts83,284 71,911 
Total inventories$132,897 $118,530 
v3.25.2
DIVESTITURE
 6 Months Ended
Jun. 30, 2025
Discontinued Operations and Disposal Groups [Abstract]  
DIVESTITURE
NOTE 4 - DIVESTITURE

In December 2024, the Company entered into a definitive agreement with Hexagon AB for the sale of its Geomagic software business ("Geomagic"), which was included in our Industrial Solutions segment. On April 1, 2025, the Company completed the sale of Geomagic and received $119.4 million in cash, which reflected applicable purchase price adjustments under the Asset Purchase Agreement and Business Transfer Agreement. The Company recorded a pre-tax gain of $125.7 million from the sale of Geomagic in the three and six months ended June 30, 2025.
No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been presented as a discontinued operation in the accompanying condensed consolidated financial statements because the sale of Geomagic does not represent a strategic shift that will have a major effect on the Company’s operations.
The Company determined that the associated assets and liabilities met the held for sale criteria in December 2024. The following table summarizes the assets and liabilities of Geomagic:

(in thousands)December 31, 2024
Assets
Accounts receivable, net$765 
Prepaid expenses and other current assets47 
Total current assets held for sale812 
Intangible assets, net917 
Other assets1,447 
Total assets held for sale$3,176 
Liabilities
Accounts payable$491 
Accrued and other liabilities303 
Deferred revenue7,197 
Total current liabilities held for sale7,991 
Other liabilities2,260 
Total liabilities held for sale$10,251 
v3.25.2
INVESTMENTS AND NOTE RECEIVABLE
 6 Months Ended
Jun. 30, 2025
Equity Method Investments and Joint Ventures [Abstract]  
INVESTMENTS AND NOTE RECEIVABLE
NOTE 5 - INVESTMENTS AND NOTE RECEIVABLE

The Company holds various equity investments. The following table summarizes our investment balances:

(in thousands)June 30, 2025December 31, 2024
Equity investments under the equity method of accounting$3,362 $5,051 
Equity investments without readily determinable fair values21,712 20,696 
Total equity investments$25,074 $25,747 

During the three months ended June 30, 2025, the Company purchased additional shares of an equity method investment in Enhatch Inc. ("Enhatch") for $0.9 million. As of June 30, 2025, the Company owns approximately 79% of Enhatch's outstanding common stock and approximately 46% of Enhatch's outstanding voting stock.

During the three months ended June 30, 2025, the Company entered into an agreement with GenesisTissue Inc. ("GenesisTissue") to obtain shares of common stock in exchange for the sale of certain assets. As of June 30, 2025, the Company owns approximately 8% of GenesisTissue's outstanding common stock. The Company has accounted for its investment in GenesisTissue on a cost basis, subject to assessment for impairment, as (1) the fair value of GenesisTissue's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The carrying value of the equity investment without a readily determinable fair value is $1.0 million as of June 30, 2025. The investment is reported in Other assets on our Condensed Consolidated Balance Sheets.
Note Receivable - Related Party
In February 2023, we became a shareholder in a joint venture, National Additive Manufacturing Innovation ("NAMI") Joint Venture, formed with the Saudi Arabian Industrial Investments Company ("Dussur") for purposes of expanding the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa.
During December 2024, the Company entered into a short-term, non-interest bearing loan agreement with NAMI whereby NAMI borrowed $2.0 million to finance its working capital and capital expenditures requirements. The loan matured on June 30, 2025 and the parties are in the process of extending the maturity date. It is being accounted for at cost, which approximates fair value as of June 30, 2025. The carrying value of the related party note receivable was $2.0 million as of June 30, 2025 and December 31, 2024. The note receivable is reported in Prepaid expenses and other current assets, on our Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024, respectively.
Additionally, during the three and six months ended June 30, 2025 and 2024, the Company entered into related party transactions with certain of our equity investments, including purchases and sales, but the transactions and related balances payable or receivable were not significant for the three and six months ended June 30, 2025 and 2024 and as of June 30, 2025 and December 31, 2024.

Other Asset
In February 2025, the Company provided financing of $1.0 million to Hull Legacy Media Corporation, a production company co-owned by Charles W. Hull, our EVP, Chief Technology Officer of our Regenerative Medicine business and a related party of the Company. The financing is recorded in Other assets on our Condensed Consolidated Balance Sheets as of June 30, 2025.

Variable Interest Entities ("VIEs")
The Company concluded that three of its investments are VIEs. These investments are not consolidated because we concluded that the Company is not the primary beneficiary. As of June 30, 2025, our maximum exposure to losses associated with the VIEs is limited to the $20.2 million carrying value of our investments in the VIEs, $2.0 million of which is included in Prepaid expenses and other current assets, with the remaining in Other assets on our Condensed Consolidated Balance Sheets. We have no other investments in unconsolidated entities that have been determined to be a VIE.
v3.25.2
BORROWINGS
 6 Months Ended
Jun. 30, 2025
Debt Disclosure [Abstract]  
BORROWINGS
NOTE 6 - BORROWINGS

Convertible Senior Notes
Convertible senior secured notes due 2030
Pursuant to an indenture dated June 23, 2025 (the "2030 Indenture"), the Company issued $92.0 million aggregate principal amount of 5.875% convertible senior secured notes due 2030 (the "2030 Notes") in a private placement to a limited number of qualified institutional buyers. The net proceeds from the 2030 Notes, along with $78.0 million of cash on hand, were used to repurchase an aggregate principal amount of $179.7 million of the Company's outstanding 0% convertible senior notes due 2026 (the “2026 Notes”). The Company believes this refinancing to be a timely and proactive step in addressing the 2026 Notes maturity in light of continuing macroeconomic challenges impacting the Company’s financial performance.
The 2030 Notes are senior secured obligations, guaranteed by certain U.S. subsidiaries of the Company (the "Note Parties"), and bear interest semiannually at a rate of 5.875%, payable on June 15 and December 15 of each year, beginning December 15, 2025. The 2030 Notes are secured on a first-priority basis by substantially all assets of Note Parties, subject to certain exceptions (including with respect to the intellectual property of Note Parties; provided that, certain breaches by the Company or any of its subsidiaries of the limitation on liens covenant in the 2030 Indenture with respect to liens on its intellectual property will cause the 2030 Notes to automatically become secured by a prior security interest in all the intellectual property of the Note Parties). The 2030 Indenture also includes certain financial covenants, including a requirement for the Note Parties to maintain certain minimum cash, accounts receivable and inventory balances each quarter. As of the last day of each fiscal quarter, the Note Parties must maintain at least $40.0 million in qualified cash; maintain a combined minimum of $75.0 million in accounts receivable and inventory; and maintain at least $16.8 million in restricted cash until the remaining 2026 Notes are settled.
The initial conversion rate was 445.6328 shares per $1,000 principal amount, equivalent to a conversion price of approximately $2.24 per share, which reflected a 20% premium over the $1.87 closing price of the Company’s common stock on June 17, 2025. The 2030 Notes are set to mature on June 15, 2030, unless earlier converted, redeemed, or repurchased. The 2030 Notes
will be convertible into cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the election of the Company.
Holders of the 2030 Notes have a one-time put right on June 23, 2028, to require the Company to repurchase all or a portion of their 2030 Notes for cash at 100% of the principal amount, plus accrued and unpaid interest. Additionally, upon a fundamental change (as defined in the 2030 Indenture), holders may require repurchase on the same terms. The Company is required to increase the conversion rate for holders who convert in connection with certain fundamental changes or in connection with a redemption.
On or after June 23, 2028 and prior to the 41st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable, in whole or in part, at the Company's option, for cash, provided that the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for a specified period, as described in the 2030 Indenture.
Convertible senior notes due 2026
The 2026 Notes were issued pursuant to an indenture dated November 16, 2021 (the “2026 Indenture”) between the Company and The Bank of New York Mellon, N.A., as trustee (the “Trustee”), in an initial aggregate principal amount of $460.0 million. Although the 2026 Notes do not bear regular interest and their principal does not accrete, they have an annual effective interest rate of 0.594%, reflecting original issue discounts, commissions, and offering expenses. The 2026 Notes had an initial conversion rate of 27.8364 shares of common stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the Indenture. The 2026 Notes are scheduled to mature on November 15, 2026, unless earlier redeemed, repurchased, or converted in accordance with their terms.
Prior to August 15, 2026, the 2026 Notes will only be convertible upon the occurrence of certain events and will be convertible thereafter at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.
The 2026 Notes are redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after November 20, 2024 and before the 41st scheduled trading day immediately preceding the maturity date, but only if the last reported sale price per share of the Company's common stock has been at least 130% of the conversion price then in effect for a specified period of time.
The Company incurred $0.3 million and $0.6 million of debt issuance cost accretion related to the 2026 Notes for the three and six months ended June 30, 2025, respectively, and $0.3 million and $0.7 million for the three and six months ended June 30, 2024, respectively.

The following tables summarize the detail of the Company's convertible senior notes:
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
June 30, 2025
0% Convertible senior notes due 2026
$34,717 (283)$34,434 
5.875% Convertible senior notes due 2030
92,030 (3,821)88,209 
Outstanding convertible notes$126,747 $(4,104)$122,643 
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
December 31, 2024
0% Convertible senior notes due 2026
$214,378 (2,383)$211,995 
Outstanding convertible notes$214,378 $(2,383)$211,995 

As of June 30, 2025, the Company was in compliance with all of the covenants included in the 2026 Indenture and 2030 Indenture.
Debt Extinguishment
In June 2025, the Company used the proceeds of $92.0 million from the issuance of the 2030 Notes, along with $78.0 million of cash on hand, to repurchase an aggregate principal amount of $179.7 million of its outstanding 2026 Notes, which were retired upon receipt, and the retirement of the debt obligations was accounted for as an extinguishment of debt. The repurchase of the 2026 Notes at a discount resulted in the recognition of a gain of $8.2 million, after transaction expenses and the write-off of $1.5 million in related debt issuance costs. The gain is reported in Other income, net on the Company’s Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025.
In March 2024, the Company repurchased $110.5 million of the 2026 Notes for $87.2 million, including transaction expenses. The repurchased 2026 Notes were retired upon receipt, and the retirement of the debt obligations was accounted for as an extinguishment of debt. The repurchase of the 2026 Notes at a discount resulted in the recognition of a gain of $21.5 million, after transaction expenses and the write-off of $1.8 million in related debt issuance costs. The gain is reported in Other income, net on the Company’s Condensed Consolidated Statements of Operations for the six months ended June 30, 2024.
v3.25.2
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION NOTE 7 - STOCK-BASED COMPENSATION
2015 Incentive Plan
The Company is authorized to grant shares of restricted stock, restricted stock units (“RSUs”), stock appreciation rights, cash incentive awards and options to purchase shares of common stock to employees and non-employee directors pursuant to its 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan also designates measures that may be used for performance awards and market-based awards. The vesting period for awards granted under the 2015 Plan is generally determined by the Board of Directors at the date of the grant. Generally, the awards vest one third each year, over 3 years.
During the three months ended June 30, 2025, the Company granted 810 thousand performance-based RSUs to employees with a weighted-average grant date fair value of $0.47 per share. The restricted stock awards vest one third each year, over 3 years. The awards include a market condition that is met based on annualized stock price growth goals. During the three months ended June 30, 2025, the Company granted 1,014 thousand shares of restricted stock to employees with a weighted-average grant date fair value of $2.02 per share. The restricted stock awards generally vest ratably over 3 years.

Stock-Based Compensation Activity and Expense
The following table shows the stock-based compensation expense recognized:

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Stock-based compensation (benefit) expense
$(3,561)$5,421 $607 $13,673 


During the three months ended June 30, 2025, the Company recognized a reversal of $6.6 million in previously recognized compensations expense, primarily due to the forfeiture of awards that did not meet performance conditions and the cancellation of annual incentive compensation.
Stock-based compensation expense recognized for the three and six months ended June 30, 2024 includes $0.7 million and $2.3 million, respectively, of accrued expense pertaining to annual incentive compensation expected to be settled in shares of common stock.
As of June 30, 2025, there was $12.9 million of unrecognized stock-based compensation expense related to all unvested share-based payment awards that the Company expects to recognize over a weighted-average period of 2 years.
dp polar Earnout
On October 4, 2022 the Company acquired dp polar. The acquisition agreement included an earnout arrangement for $2.2 million incremental to the acquisition purchase price, which would be settled via the issuance of 250 thousand shares of the Company's common stock. During the three months ended June 30, 2025, the dp polar earnout was settled through the issuance of 250 thousand shares of the Company's common stock. There was no stock-based compensation expense related to the dp polar earnout arrangement for the three and six months ended June 30, 2025, respectively, and $0.7 million and $1.0 million, for the three and six months ended June 30, 2024, respectively.
v3.25.2
INCOME TAXES
 6 Months Ended
Jun. 30, 2025
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE 8 - INCOME TAXES

We maintain the exception under ASC 740-270-30-36(b), “Accounting for Income Taxes,” for jurisdictions that do not have reliable estimates of ordinary income. Accordingly, we have used a year-to-date methodology in determining the effective tax rate for the three and six months ended June 30, 2025 and 2024.
For the three and six months ended June 30, 2025, the Company's effective tax rate was 9.4% and 14.4%, respectively. For the three and six months ended June 30, 2024 the Company’s effective tax rate was (1.8)% and (4.6)%, respectively. The differences between the U.S. statutory tax rate and the effective tax rates for the three and six months ended June 30, 2025 and 2024 were primarily driven by the recognition of a full deferred tax asset valuation allowance in various jurisdictions in both years. Additionally, the three and six months ended June 30, 2025 were impacted by the gain recognized in connection with the divestiture of Geomagic.
On July 4, 2025, the U.S. enacted H.R. 1, commonly referred to as the One Big Beautiful Bill Act (OBBBA). The Company is continuing to evaluate the impacts of the new legislation on the Consolidated Financial Statements.
v3.25.2
NET INCOME (LOSS) PER SHARE
 6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER SHARE
NOTE 9 - NET INCOME (LOSS) PER SHARE

Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to 3D Systems’ common stock by the weighted average number of shares of common stock outstanding during the applicable period. Diluted net income (loss) per common share incorporates the additional shares issuable upon the assumed exercise of stock options, the vesting of restricted stock and RSUs, and the assumed conversion of debt, except in such case when (1) the inclusion of such shares or potential shares would be anti-dilutive or (2) when the vesting of restricted stock or RSUs is contingent upon one or more performance conditions that have not been met as of the balance sheet date.

Three Months Ended Six Months Ended
(in thousands, except per share amounts)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Numerator (basic):
Net income (loss) attributable to 3D Systems Corporation$104,436 $(27,258)$67,450 $(43,259)
Redeemable non-controlling interest redemption value in excess of carrying value— (98)— (173)
Net income (loss) attributable to 3D Systems' common stock shareholders$104,436 $(27,356)$67,450 $(43,432)
Numerator (diluted):
Net income (loss) attributable to 3D Systems' common stock shareholders$104,436 $(27,356)$67,450 $(43,432)
Add back: Interest on 2030 Notes104 — 104 — 
Net income (loss) attributable to 3D Systems' common stock shareholders plus assumed conversions$104,540 $(27,356)$67,554 $(43,432)
Denominator:
Basic weighted average common shares outstanding(a)
132,280 131,802 132,370 131,311 
Effect of Dilutive securities:
Restricted stock and RSUs1,222 — 1,653 — 
Conversion of 2030 Notes49,214 — 49,214 — 
Diluted weighted average common shares outstanding182,716 131,802 183,237 131,311 
Net income (loss) per common share:
Basic$0.79 $(0.21)$0.51 $(0.33)
Diluted$0.57 $(0.21)$0.37 $(0.33)
Anti-dilutive shares4,075 3,553 2,929 4,489 
(a) For the three and six months ended June 30, 2025, includes 250 thousand shares of common stock issued in April 2025 in connection with the dp polar earnout arrangement.
In the three and six months ended June 30, 2025 approximately 0 and 146 thousand shares, respectively, related to the payment of accrued incentive compensation that was settled in shares, were included in diluted shares. In the three and six months ended June 30, 2024, approximately 0 shares and 531 thousand shares, respectively, related to the payment of accrued incentive compensation that was settled in shares, were included in diluted shares. These estimates are based on the liabilities recorded as of June 30, 2025 and June 30, 2024, under the fiscal year 2025 and 2024 incentive compensation arrangements, respectively, divided by the Company’s year-to-date average share price of $2.60 for 2025 and $4.28 for 2024.
Diluted income per common share was computed using the treasury stock method for restricted shares and RSUs and the if-converted method for convertible debt.
Share Repurchases
On June 23, 2025, 3D Systems repurchased 8.0 million shares of its outstanding common stock at a price of $1.87 per share, which was equal to the closing price of the common stock on the New York Stock Exchange on June 17, 2025. The share repurchase was executed concurrently with the issuance of $92 million of new 5.875% Convertible Senior Secured Notes due 2030 (refer to Note 6).
The share repurchase was approved by the Company’s Board of Directors in connection with the broader refinancing transaction. It was structured to mitigate potential dilution associated with the issuance of the new convertible notes and was funded as part of the same transaction that retired a significant portion of the Company’s 2026 Notes at a discount to par. The Company retired its common stock upon repurchase.
v3.25.2
ACCUMULATED OTHER COMPREHENSIVE LOSS
 6 Months Ended
Jun. 30, 2025
Stockholders' Equity Note [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE LOSS
NOTE 10 - ACCUMULATED OTHER COMPREHENSIVE LOSS

The changes in the balances of accumulated other comprehensive loss, net of tax, by component are as follows:

Three Months Ended June 30, 2025
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, March 31, 2025$(52,171)$157 $(52,014)
Other comprehensive income 9,075 14 9,089 
Balance, June 30, 2025$(43,096)$171 $(42,925)
Three Months Ended June 30, 2024
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, March 31, 2024$(51,750)$307 $(51,443)
Other comprehensive loss(1,196)(2)(1,198)
Balance, June 30, 2024$(52,946)$305 $(52,641)

Six Months Ended June 30, 2025
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, December 31, 2024$(55,217)$151 $(55,066)
Other comprehensive income12,121 20 12,141 
Balance, June 30, 2025$(43,096)$171 $(42,925)
Six Months Ended June 30, 2024
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, December 31, 2023$(44,564)$314 $(44,250)
Other comprehensive loss(8,382)(9)(8,391)
Balance, June 30, 2024$(52,946)$305 $(52,641)
v3.25.2
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION
NOTE 11 - SEGMENT INFORMATION

Our chief operating decision maker ("CODM"), who is our President and Chief Executive Officer, is responsible for reviewing segment performance and making decisions regarding resource allocation. Our CODM regularly reviews the results of our business through two reportable segments: Healthcare Solutions and Industrial Solutions, which are based on the industry verticals they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing.
The CODM evaluates each segment’s performance based on gross profit, which is also utilized in the annual budgeting and forecasting processes, as well as in quarterly reviews of budget-to-actual results and period-over-period variances. All internal segment reporting and discussions with the CODM are now based on segment gross profit. Prior period segment results have been revised to conform with current period presentation.
The CODM does not review disaggregated asset information on the basis of the Company's segments; therefore, such information is not presented.

Revenue, cost of sales and gross profit for each of our reportable segments were as follows:

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Revenue:
Healthcare Solutions$45,020 $48,900 $86,336 $94,313 
Industrial Solutions49,818 64,352 103,042 121,844 
Total revenue94,838 113,252 189,378 216,157 
Cost of sales:
Healthcare Solutions24,638 26,465 49,930 54,896 
Industrial Solutions34,050 39,689 70,609 73,241 
Total cost of sales58,688 66,154 120,539 128,137 
Gross profit:
Healthcare Solutions20,382 22,435 36,406 39,417 
Industrial Solutions15,768 24,663 32,433 48,603 
Total gross profit36,150 47,098 68,839 88,020 
Selling, general and administrative34,139 51,494 83,908 108,798 
Research and development17,361 22,016 37,044 45,496 
Foreign exchange gain (loss), net(1,591)(723)(452)1,186 
Interest income1,717 1,452 2,670 4,250 
Interest expense(697)(624)(1,278)(1,338)
Gain on disposition125,681 — 125,681 — 
Other income, net7,020 384 6,860 21,770 
Net income (loss) before income taxes
$116,780 $(25,923)$81,368 $(40,406)

Depreciation and amortization included in the measurement of gross profit by segment were as follows:

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Depreciation and amortization:
Healthcare Solutions
$1,201 $1,365 $2,685 $2,720 
Industrial Solutions
$671 $782 $1,293 $1,531 
v3.25.2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2025
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 12 - COMMITMENTS AND CONTINGENCIES

The Company has certain purchase commitments under agreements with remaining terms in excess of one year primarily related to printer assemblies, inventory, capital expenditures, and software licenses. As of June 30, 2025, such purchase commitments totaled $19.8 million, with $10.3 million of the purchase obligations expected to be due within the next twelve months.

Indemnification
In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant, and we are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.
To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments that we could be required to make under these indemnification obligations is unlimited; however, we have directors and officers insurance coverage that may enable us to recover future amounts paid, subject to a deductible and the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

Other Commitments
Government Settlement
In October 2017, the Company undertook an internal investigation relating to possible violations of U.S. export control laws, including the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State (“DDTC”) and the Export Administration Regulations administered by the Bureau of Industry and Security of the Department of Commerce (“BIS”). In February 2023, the Company settled these matters with the U.S. Department of Justice (“DOJ”), DDTC and BIS. As a part of these settlement agreements, the Company agreed to pay $15.0 million in civil monetary penalties to these agencies, with an additional $10.0 million suspended penalty amount to be allocated to remedial compliance measures required by DDTC. The penalty amounts subject to payment were broken down as follows: DDTC, $10.0 million (payable in three installments over a three-year period); BIS, $2.8 million; and DOJ, $2.3 million.
During the three months ended March 31, 2025, we paid the final installment penalty of $3.0 million in accordance with the DDTC settlement agreement. The original $10.0 million suspended penalty has not been recognized as a liability, as it will be recognized as incurred for remedial compliance measures during the three-year term of the settlement agreement. The application of the Company’s spend on remedial compliance measures as a reduction to the original $10.0 million suspended penalty must be approved by DDTC, which approval will be sought on an annual basis in accordance with the terms of the settlement agreement. As of June 30, 2025, the approved suspended penalty balance remaining is $5.1 million. Any portion not expended for compliance measures at the end of the three-year term of the settlement agreement will be paid by the Company to DDTC.

Letter of Credit
On June 2, 2023, we issued $1.2 million of guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The letter of credit has a maturity date in June 2026 and includes automatic one-year extensions, which are not to continue beyond July 1, 2033. As of June 30, 2025, the letter of credit has been reduced to $0.8 million. We have not recorded any liability for this guarantee, as we believe that the likelihood of having to perform under the letter of credit is remote. In connection with this transaction, we pledged an equal amount of cash to the issuing bank of this letter of credit. The cash pledged is recorded as restricted cash and included in Other assets on our Condensed Consolidated Balance Sheets.

Litigation
SEC Investigation
On April 15, 2022, the Company was informed that the SEC is conducting a formal investigation of the Company related to, among other things, allegations that had been brought against the Company in a securities class action lawsuit that was brought against the Company in 2021 and settled in January 2024. The Company has subsequently received subpoenas from the SEC for the production of documents and information related to its investigation as a follow on to a previous voluntary request for documents. The most recent SEC subpoena was received by the Company in August 2024, and requested additional documents and information relating to its continuing investigation of the Company. The Company completed its submission of this
additional information to the SEC by the end of November 2024. The Company is continuing to cooperate with the SEC in connection with its formal investigation.

Termination of Volumetric Milestones Related to Potential Earnout Payments
Following the acquisition of Volumetric in 2021, the Company could have been required to pay up to $355.0 million of acquisition-related earnout payments to the former owners of Volumetric if the Company were to achieve seven non-financial, science-based milestones prior to either December 31, 2030 or December 31, 2035. Due to the loss of funding from the Company's key strategic partner for kidney and liver research and development efforts, the Company notified the former owners of Volumetric on February 24, 2024 that it was terminating the four milestones that related to those kidney and liver research and development efforts, as achievement was no longer financially viable. As a result of the termination of the four milestones, the Company's maximum liability for acquisition-related earnout payments was reduced to $175.0 million, which would have been payable if each of the three remaining non-financial, science-based milestones was achieved within the timeframes set forth in the Volumetric acquisition agreement.
On March 29, 2024, the former owners of Volumetric notified the Company that they were initiating dispute resolution under the provisions of the acquisition agreement in an effort to recover the $355.0 million. The parties did not reach a resolution during the 30-day negotiation period following this notice and now have entered into non-binding mediation in accordance with the terms of the acquisition agreement.
On April 29, 2024, two key employees from Volumetric ("Volumetric Key Employees"), who were required to be employed at the time of achievement of each non-financial, science-based milestone outlined in the Volumetric acquisition agreement for each related acquisition earnout payment to become payable, resigned from their positions with the Company. As a result of the resignation of the Volumetric Key Employees, all parties to which the remaining three milestone-based earnout payments totaling $175.0 million were potentially payable were notified that such amount was no longer eligible to be earned. While the Volumetric Key Employees claim that their terminations were for good reason, which would preserve the rights to milestone-based earnout payments under the Volumetric acquisition agreement, the Company vigorously denies this claim. Presently, no lawsuit has been filed by the former owners of Volumetric to which milestone-based earnout payments were potentially payable, and there is no reasonable estimate or range of estimates of potential financial liability associated with this matter.
On August 21, 2024, the Company proposed a settlement of $1.8 million with the former shareholders and Volumetric Key Employees during mediation and this amount is recorded within Accrued and other liabilities on our Condensed Consolidated Balance Sheets as of June 30, 2025. The former shareholders have not responded to the settlement offer. On December 13, 2024, the Company received a Notice of Claim for Indemnification from VBI Stockholders’ Representative, LLC., which claims to be the successor Stockholders’ Representative under the acquisition agreement. The Notice repeated the former shareholders’ and Volumetric Key Employees' claims of breach. On January 10, 2025, the Company served a Notice of Objection which denied all liability. The delivery of this Notice of Objection triggered a 45-day negotiation period under the terms of the acquisition agreement. As of August 11, 2025, the Company has not heard anything further from the former shareholders and Volumetric Key Employees regarding this matter.

Intrepid Automation
On May 19, 2021, 3D Systems, Inc. initiated a lawsuit in the Superior Court of the State of California for the County of San Diego against five former employees and Intrepid Automation, Inc. (collectively, the “Intrepid Parties”) alleging theft of trade secrets, unfair competition, breach of contract, and related claims (“2021 Lawsuit”). In June 2021, this lawsuit was removed to the United States District Court for the Southern District of California. In September 2022, the Intrepid Parties filed counterclaims against 3D Systems, Inc. In September 2022, the Company filed a motion to dismiss these counterclaims; this motion was granted in part in May 2023. The Intrepid Parties filed amended counterclaims in May 2023 alleging theft of trade secrets, fraudulent inducement, breach of contract, unfair competition, and related claims; this amended complaint sought damages in excess of $20 million as well as injunctive relief. These counterclaims were partially dismissed in March 2024 in response to a second motion to dismiss filed by the Company. The parties filed motions for summary judgment in April and May 2024. In March 2025, the Court granted the Intrepid Parties’ motion, dismissing the Company’s claims against the Intrepid Parties, but denied the Company’s motion for summary judgment with respect to the counterclaims brought by the Intrepid Parties in the 2021 Lawsuit. On April 17, 2025, the Company filed motions asking the Court to reconsider its dismissal of the Company's claims or granting a partial final judgment so that the Company may appeal the dismissal.
On December 4, 2024, Intrepid Automation, Inc. (“Intrepid”) filed a lawsuit in the United States District Court for the Southern District of California against 3D Systems Corporation and 3D Systems, Inc. alleging infringement of U.S. patents 11,014,301 and 11,338,511 (“2024 Lawsuit”); this complaint seeks unspecified damages and injunctive relief. In July 2025, the Company filed inter partes review (“IPR”) petitions against the asserted patents, and on July 16, 2025, the Company filed a motion to stay the 2024 Lawsuit pending resolution of the IPRs.
The Company intends to defend itself vigorously against the 2024 Lawsuit and the counterclaims in the 2021 Lawsuit.

Securities Class Action
The Company and certain of its executive offers were named as defendants in a putative securities class action filed on June 13, 2025 in the U.S. District Court for the District of Delaware. The action is styled Marcel F.M. Herbermann v. 3D Systems Corporation, et al., No. 1:25-cv-00734-GBW (D. Del.) (the “Securities Class Action”). The complaint in the Securities Class Action alleges defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that the executive officers named as defendants are control persons under Section 20(a) of the Exchange Act. It was filed on behalf of stockholders who purchased the Company’s common stock from August 13, 2024 and May 12, 2025, and seeks monetary damages on behalf of the purported class. Defendants’ deadline to answer, move to dismiss, or otherwise respond to the complaint in the Securities Class Action is September 22, 2025. The Company intends to defend itself and its executive officers vigorously.

Derivative Actions
The Company was named as a nominal defendant and certain of its officers and directors were named as defendants in derivative lawsuits pending in the U.S. District Court for the District of South Carolina and the South Carolina Court of Common Pleas for the 16th Circuit, York County (the “Derivative Actions”). The action styled Fernicola v. Graves, et al., No. 2025CP4602544 (S.C., Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the “Fernicola Action”) was filed June 27, 2025, and asserts claims for breach of fiduciary duties, gross mismanagement, waste of corporate assets, and unjust enrichment. The action styled Scanlon v. Graves, et al., No. 0:25-cv-07627-MGL (D.S.C.) (the “Scanlon Action”) was filed July 17, 2025, and asserts claims for violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder, breach of fiduciary duties, and unjust enrichment. Defendants’ deadline to answer, move to dismiss, or otherwise respond to the complaint in the Fernicola Action is August 29, 2025 and Defendants’ deadline to answer, move to dismiss, or otherwise respond to the complaint in the Scanlon Action is September 22, 2025. The Company intends to defend itself as well as its officers and directors vigorously.
We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all of these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position.

Contingencies
Warranty
Changes in accrued product warranty liability balance are summarized as follows:

(in thousands)June 30, 2025June 30, 2024
Balance at beginning of period$2,650 $2,106 
Settlements made(1,548)(1,770)
Accruals for warranties issued2,350 858 
Balance at the end of period$3,452 $1,194 
v3.25.2
FAIR VALUE MEASUREMENTS
 6 Months Ended
Jun. 30, 2025
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 13 - FAIR VALUE MEASUREMENTS

Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy:

•Level 1 - Inputs are based on quoted prices in active markets for identical assets and liabilities.
•Level 2 - Inputs are based on observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
•Level 3 - One or more inputs are unobservable and significant.
Financial and nonfinancial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Recurring Fair Value Measurements
The following table summarizes financial assets and financial liabilities that are measured and recorded in the consolidated financial statements at fair value on a recurring basis:
(in thousands)
Fair Value Measurement Using (a)
June 30, 2025Total Fair ValueLevel 1Level 2Level 3
Money market funds$54,562 $54,562 $— $— 
December 31, 2024
Money market funds$98,212 $98,212 $— $— 
(a) There were no transfers among the levels within the fair value hierarchy during the six months ended June 30, 2025 or the year ended December 31, 2024.
Cash equivalents, including money market funds, are valued utilizing the market approach for measuring the fair value of financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of June 30, 2025 and December 31, 2024 because of the relatively short duration of these instruments.
Fair Value of Financial Instruments
The following table summarizes the carrying amount and fair value of our financial instruments:
June 30, 2025December 31, 2024
(in thousands)Carrying AmountFair ValueCarrying AmountFair Value
0% Convertible senior notes due 2026
$34,434 $30,443 $211,995 $189,409 
5.875% Convertible senior secured notes due 2030
$88,209 $92,030 $— $— 
The estimated fair value of the 2026 Notes was determined using quoted market price in a market with limited activity, and is therefore classified as Level 2 in the fair value hierarchy. The estimated fair value of the 2030 Notes was based on par value, as there has been no market activity since issuance. As a result, the fair value of the 2030 Notes is classified as Level 3.
v3.25.2
RESTRUCTURING AND EXIT ACTIVITIES COSTS
 6 Months Ended
Jun. 30, 2025
Restructuring and Related Activities [Abstract]  
RESTRUCTURING AND EXIT ACTIVITIES COSTS
NOTE 14 - RESTRUCTURING AND EXIT ACTIVITIES COSTS

The Company incurs restructuring charges in connection with strategic initiatives and cost-reduction efforts aimed at optimizing business operations. A description of significant restructuring plans and other restructuring charges is provided below.

2025 Restructuring
In 2025, in response to continuing macroeconomic challenges impacting the Company’s financial performance, the Company implemented a series of cost savings and restructuring initiatives ( the "2025 Restructuring Plan") as part of its ongoing multi-
faceted transformation strategy. In March 2025, the Company authorized and began executing the next phase of its cost savings and restructuring initiative which includes initiatives to deliver sustainable growth and profitability, enabled by a streamlining of both infrastructure and business processes, while consistently investing in core research and development activities to support long-term growth opportunities. In May 2025, the Company announced and began executing an incremental cost reduction initiative focused on labor force reductions in response to continued uncertainty in the economy and our industry and the related potential negative impact on our financial performance. These initiatives are expected to deliver cost savings and improve cash flows in the second half of fiscal 2025.
The Company expects to incur approximately $11 million to $20 million in pre-tax restructuring charges, primarily related to employee severance and other one-time employee benefit costs. These charges are anticipated to consist largely of cash expenditures and are expected to be recognized primarily in 2025 and through the second fiscal quarter of 2026.
Restructuring and other related charges were as follows:
Three Months EndedSix Months Ended
(in thousands)
June 30, 2025 (a)
 June 30, 2024 (b)
June 30, 2025 (a)
 June 30, 2024 (b)
Employee severance related$5,145 $(402)$6,142 $(351)
Facility exit and other related— 489 — 489 
Total $5,145 $87 $6,142 $138 
(a) Includes expenses related to the 2025 Restructuring Plan
(b) Includes expenses related to the 2023 Restructuring Plan

The restructuring and other related charges were primarily cash charges. These charges are reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations as follows:                                                                                                
Three Months EndedSix Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Cost of sales$838 $(1,025)$1,001 $(992)
Selling, general, and administrative expenses3,622 873 4,180 891
Research and development685 239 961 239
Total$5,145 $87 $6,142 $138 

Restructuring and other related charges recorded in cost of sales by reportable segment were as follows:
Three Months EndedSix Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Healthcare Solutions$458 $(1,025)$512 $(992)
Industrial Solutions380 — 489 — 
Total$838 $(1,025)$1,001 $(992)

The activity in the restructuring accrual related to the 2025 Restructuring Plan was as follows:
(in thousands)Balance as of December 31, 2024Costs IncurredPaid/SettledBalance as of June 30, 2025
Employee severance related$— $6,142 $(1,962)$4,180 
Total$— $6,142 $(1,962)$4,180 

2023 Restructuring Plan
In 2023, the Company initiated a restructuring plan aimed at improving operational efficiency and driving long-term value creation (the "2023 Restructuring Plan"). Key initiatives included in-sourcing certain European metal printer platforms to the Company’s Riom, France facility, co-locating engineering and manufacturing functions to accelerate the development-to-production cycle, reducing headcount across all areas of the organization, and exiting select leased facilities to streamline the Company’s geographic footprint. Substantially all restructuring activities related to the 2023 Restructuring Plan were completed as of the year ended December 31, 2024.
v3.25.2
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.2
BASIS OF PRESENTATION (Policies)
 6 Months Ended
Jun. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Consolidated Entities
Consolidated Entities
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all majority-owned and wholly-owned subsidiaries and entities in which a controlling interest is maintained. Intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current year presentation.
Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 ( the “2024 Annual Report on Form 10-K”). The Company believes that the disclosures included in this Form 10-Q are adequate to make the information presented not misleading. In the opinion of management, the unaudited condensed consolidated financial statements contain all adjustments, consisting of adjustments of a normal recurring nature, necessary to present fairly the Company's financial position, results of operations, and cash flows for the periods presented. The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results may differ from those estimates and assumptions.Our annual reporting period is the calendar year. The Company's results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the full year.
Goodwill
Goodwill
Based primarily on macroeconomic uncertainties, our updated strategic plans and restructuring initiatives and the decline in our stock price during the second quarter of 2025, we concluded that changes to the timing and amount of expected future cash flows, among other factors, indicated a triggering event requiring an interim goodwill impairment assessment of our Healthcare reporting unit. As a result of the quantitative interim impairment test performed in the second quarter of 2025, we concluded that there was no impairment, as the estimated fair value of the Healthcare reporting unit exceeded the carrying value.
To determine the fair value of the reporting unit, we performed our impairment test using a combination of an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 26.2%. The discount rate was based on the weighted average cost of capital, determined using market, and industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment.
While there was no impairment found during our interim goodwill impairment test in the second quarter of 2025, changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairments tests could affect the implied fair value of goodwill and may result in impairment charges in the future.
Recently Adopted Accounting Standards / Recently Issued Accounting Standards Not Yet Adopted
Recently Adopted Accounting Standards
In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments," related to induced conversions of convertible debt instruments. The amendments in this ASU clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions rather than as debt extinguishments. The Company early adopted this ASU as of April 1, 2025 and applied the guidance on a prospective basis. Adoption did not have a material impact on our condensed consolidated financial statements.

Recently Issued Accounting Standards Not Yet Adopted
In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, while permitted to be adopted on a retrospective basis. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Upon adoption, this ASU is expected to result in the inclusion of additional tax-related disclosures in the footnotes to our consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The amendments in this ASU require public entities to provide disaggregated disclosure of expenses included within relevant income statement expense captions, as well as additional disclosures about selling expenses. This update is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments in this ASU should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of the ASU or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is currently in the process of evaluating the effects of this ASU on our consolidated financial statements.
v3.25.2
REVENUES (Tables)
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Contract Liabilities
Our contract liabilities consisted of the following:
(in thousands)June 30, 2025December 31, 2024
Deferred revenue, current and customer deposits$39,394 $32,010 
Deferred revenue, noncurrent3,652 2,259 
Total contract liabilities$43,046 $34,269 
Schedule of Revenue by Geographic Region
Revenue, by the geographic region in which a sale originated, was as follows:
Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Americas
$55,317 $66,179 $107,252 $126,784 
EMEA
33,140 37,537 66,575 71,437 
APAC6,381 9,536 15,551 17,936 
Total$94,838 $113,252 $189,378 $216,157 

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
United States (included within Americas)
$54,632 $65,432 $105,531 $125,325 
Germany (included within EMEA)
12,879 17,303 29,862 31,545 
v3.25.2
INVENTORIES (Tables)
 6 Months Ended
Jun. 30, 2025
Inventory Disclosure [Abstract]  
Schedule of Components of Inventories
(in thousands)June 30, 2025December 31, 2024
Raw materials$46,659 $43,138 
Work in process2,954 3,481 
Finished goods and parts83,284 71,911 
Total inventories$132,897 $118,530 
v3.25.2
DIVESTITURE (Tables)
 6 Months Ended
Jun. 30, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Long-Lived Assets Held-for-Sale The following table summarizes the assets and liabilities of Geomagic:
(in thousands)December 31, 2024
Assets
Accounts receivable, net$765 
Prepaid expenses and other current assets47 
Total current assets held for sale812 
Intangible assets, net917 
Other assets1,447 
Total assets held for sale$3,176 
Liabilities
Accounts payable$491 
Accrued and other liabilities303 
Deferred revenue7,197 
Total current liabilities held for sale7,991 
Other liabilities2,260 
Total liabilities held for sale$10,251 
v3.25.2
INVESTMENTS AND NOTE RECEIVABLE (Tables)
 6 Months Ended
Jun. 30, 2025
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Equity Investments The following table summarizes our investment balances:
(in thousands)June 30, 2025December 31, 2024
Equity investments under the equity method of accounting$3,362 $5,051 
Equity investments without readily determinable fair values21,712 20,696 
Total equity investments$25,074 $25,747 
v3.25.2
BORROWINGS (Tables)
 6 Months Ended
Jun. 30, 2025
Debt Disclosure [Abstract]  
Schedule of Convertible Notes Payable
The following tables summarize the detail of the Company's convertible senior notes:
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
June 30, 2025
0% Convertible senior notes due 2026
$34,717 (283)$34,434 
5.875% Convertible senior notes due 2030
92,030 (3,821)88,209 
Outstanding convertible notes$126,747 $(4,104)$122,643 
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
December 31, 2024
0% Convertible senior notes due 2026
$214,378 (2,383)$211,995 
Outstanding convertible notes$214,378 $(2,383)$211,995 
v3.25.2
STOCK-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense
The following table shows the stock-based compensation expense recognized:

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Stock-based compensation (benefit) expense
$(3,561)$5,421 $607 $13,673 
v3.25.2
NET INCOME (LOSS) PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Schedule of Net Income (Loss) Per Share Reconciliation
Three Months Ended Six Months Ended
(in thousands, except per share amounts)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Numerator (basic):
Net income (loss) attributable to 3D Systems Corporation$104,436 $(27,258)$67,450 $(43,259)
Redeemable non-controlling interest redemption value in excess of carrying value— (98)— (173)
Net income (loss) attributable to 3D Systems' common stock shareholders$104,436 $(27,356)$67,450 $(43,432)
Numerator (diluted):
Net income (loss) attributable to 3D Systems' common stock shareholders$104,436 $(27,356)$67,450 $(43,432)
Add back: Interest on 2030 Notes104 — 104 — 
Net income (loss) attributable to 3D Systems' common stock shareholders plus assumed conversions$104,540 $(27,356)$67,554 $(43,432)
Denominator:
Basic weighted average common shares outstanding(a)
132,280 131,802 132,370 131,311 
Effect of Dilutive securities:
Restricted stock and RSUs1,222 — 1,653 — 
Conversion of 2030 Notes49,214 — 49,214 — 
Diluted weighted average common shares outstanding182,716 131,802 183,237 131,311 
Net income (loss) per common share:
Basic$0.79 $(0.21)$0.51 $(0.33)
Diluted$0.57 $(0.21)$0.37 $(0.33)
Anti-dilutive shares4,075 3,553 2,929 4,489 
(a) For the three and six months ended June 30, 2025, includes 250 thousand shares of common stock issued in April 2025 in connection with the dp polar earnout arrangement.
v3.25.2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
 6 Months Ended
Jun. 30, 2025
Stockholders' Equity Note [Abstract]  
Schedule of Accumulated Other Comprehensive Loss
The changes in the balances of accumulated other comprehensive loss, net of tax, by component are as follows:

Three Months Ended June 30, 2025
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, March 31, 2025$(52,171)$157 $(52,014)
Other comprehensive income 9,075 14 9,089 
Balance, June 30, 2025$(43,096)$171 $(42,925)
Three Months Ended June 30, 2024
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, March 31, 2024$(51,750)$307 $(51,443)
Other comprehensive loss(1,196)(2)(1,198)
Balance, June 30, 2024$(52,946)$305 $(52,641)

Six Months Ended June 30, 2025
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, December 31, 2024$(55,217)$151 $(55,066)
Other comprehensive income12,121 20 12,141 
Balance, June 30, 2025$(43,096)$171 $(42,925)
Six Months Ended June 30, 2024
(in thousands)Foreign currency translation adjustmentDefined benefit pension planTotal
Balance, December 31, 2023$(44,564)$314 $(44,250)
Other comprehensive loss(8,382)(9)(8,391)
Balance, June 30, 2024$(52,946)$305 $(52,641)
v3.25.2
SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
Revenue, cost of sales and gross profit for each of our reportable segments were as follows:

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Revenue:
Healthcare Solutions$45,020 $48,900 $86,336 $94,313 
Industrial Solutions49,818 64,352 103,042 121,844 
Total revenue94,838 113,252 189,378 216,157 
Cost of sales:
Healthcare Solutions24,638 26,465 49,930 54,896 
Industrial Solutions34,050 39,689 70,609 73,241 
Total cost of sales58,688 66,154 120,539 128,137 
Gross profit:
Healthcare Solutions20,382 22,435 36,406 39,417 
Industrial Solutions15,768 24,663 32,433 48,603 
Total gross profit36,150 47,098 68,839 88,020 
Selling, general and administrative34,139 51,494 83,908 108,798 
Research and development17,361 22,016 37,044 45,496 
Foreign exchange gain (loss), net(1,591)(723)(452)1,186 
Interest income1,717 1,452 2,670 4,250 
Interest expense(697)(624)(1,278)(1,338)
Gain on disposition125,681 — 125,681 — 
Other income, net7,020 384 6,860 21,770 
Net income (loss) before income taxes
$116,780 $(25,923)$81,368 $(40,406)

Depreciation and amortization included in the measurement of gross profit by segment were as follows:

Three Months Ended Six Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Depreciation and amortization:
Healthcare Solutions
$1,201 $1,365 $2,685 $2,720 
Industrial Solutions
$671 $782 $1,293 $1,531 
v3.25.2
COMMITMENTS AND CONTINGENCIES (Tables)
 6 Months Ended
Jun. 30, 2025
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Product Warranty Liability
Changes in accrued product warranty liability balance are summarized as follows:

(in thousands)June 30, 2025June 30, 2024
Balance at beginning of period$2,650 $2,106 
Settlements made(1,548)(1,770)
Accruals for warranties issued2,350 858 
Balance at the end of period$3,452 $1,194 
v3.25.2
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 30, 2025
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table summarizes financial assets and financial liabilities that are measured and recorded in the consolidated financial statements at fair value on a recurring basis:
(in thousands)
Fair Value Measurement Using (a)
June 30, 2025Total Fair ValueLevel 1Level 2Level 3
Money market funds$54,562 $54,562 $— $— 
December 31, 2024
Money market funds$98,212 $98,212 $— $— 
(a) There were no transfers among the levels within the fair value hierarchy during the six months ended June 30, 2025 or the year ended December 31, 2024.
Schedule of Fair Value of Financial Instruments
The following table summarizes the carrying amount and fair value of our financial instruments:
June 30, 2025December 31, 2024
(in thousands)Carrying AmountFair ValueCarrying AmountFair Value
0% Convertible senior notes due 2026
$34,434 $30,443 $211,995 $189,409 
5.875% Convertible senior secured notes due 2030
$88,209 $92,030 $— $— 
v3.25.2
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Tables)
 6 Months Ended
Jun. 30, 2025
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Related Costs
Restructuring and other related charges were as follows:
Three Months EndedSix Months Ended
(in thousands)
June 30, 2025 (a)
 June 30, 2024 (b)
June 30, 2025 (a)
 June 30, 2024 (b)
Employee severance related$5,145 $(402)$6,142 $(351)
Facility exit and other related— 489 — 489 
Total $5,145 $87 $6,142 $138 
(a) Includes expenses related to the 2025 Restructuring Plan
(b) Includes expenses related to the 2023 Restructuring Plan
These charges are reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations as follows:                                                                                                
Three Months EndedSix Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Cost of sales$838 $(1,025)$1,001 $(992)
Selling, general, and administrative expenses3,622 873 4,180 891
Research and development685 239 961 239
Total$5,145 $87 $6,142 $138 

Restructuring and other related charges recorded in cost of sales by reportable segment were as follows:
Three Months EndedSix Months Ended
(in thousands)June 30, 2025June 30, 2024June 30, 2025June 30, 2024
Healthcare Solutions$458 $(1,025)$512 $(992)
Industrial Solutions380 — 489 — 
Total$838 $(1,025)$1,001 $(992)

The activity in the restructuring accrual related to the 2025 Restructuring Plan was as follows:
(in thousands)Balance as of December 31, 2024Costs IncurredPaid/SettledBalance as of June 30, 2025
Employee severance related$— $6,142 $(1,962)$4,180 
Total$— $6,142 $(1,962)$4,180 
v3.25.2
BASIS OF PRESENTATION (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Number of reportable segments | segment     2    
Short-term finance lease obligations $ 1.6   $ 1.6   $ 1.5
Long-term finance lease liabilities 10.1   10.1   $ 10.5
Amortization expense $ 0.6 $ 2.1 $ 1.2 $ 4.1  
Goodwill discount rate (in percent) 26.20%   26.20%    
v3.25.2
REVENUES (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Contract with customer, asset $ 500   $ 500   $ 300
Amounts included in contract liability at the beginning of period 11,100   25,100    
Revenue 94,838 $ 113,252 189,378 $ 216,157  
Product cost of sales $ 58,688 $ 66,154 $ 120,539 $ 128,137  
One Customer | Revenue from Contract with Customer Benchmark | Customer Concentration Risk          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Concentration risk (as a percentage) 9.70% 16.00% 10.80% 16.10%  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Axis]: 2025-07-01          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Outstanding performance obligation $ 6,400   $ 6,400    
Remaining performance obligation (as a percentage) 90.00%   90.00%    
Performance obligations expected to be satisfied, expected timing 2 years   2 years    
Collaborative Arrangement          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Revenue $ 3,600 $ 1,800 $ 6,400 $ 3,800  
Product cost of sales $ 1,300 $ 1,300 $ 3,800 $ 3,400  
v3.25.2
REVENUES (Schedule of Contract with Customer, Contract Asset, Contract Liability, and Receivable) (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]    
Deferred revenue, current and customer deposits $ 39,394 $ 32,010
Deferred revenue, noncurrent 3,652 2,259
Total contract liabilities $ 43,046 $ 34,269
v3.25.2
REVENUES (Schedule of Revenue by Geographic Region) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Disaggregation of Revenue [Line Items]        
Total revenue $ 94,838 $ 113,252 $ 189,378 $ 216,157
Americas        
Disaggregation of Revenue [Line Items]        
Total revenue 55,317 66,179 107,252 126,784
United States (included in Americas above)        
Disaggregation of Revenue [Line Items]        
Total revenue 54,632 65,432 105,531 125,325
EMEA        
Disaggregation of Revenue [Line Items]        
Total revenue 33,140 37,537 66,575 71,437
Germany (included in EMEA above)        
Disaggregation of Revenue [Line Items]        
Total revenue 12,879 17,303 29,862 31,545
APAC        
Disaggregation of Revenue [Line Items]        
Total revenue $ 6,381 $ 9,536 $ 15,551 $ 17,936
v3.25.2
INVENTORIES (Components of Inventories) (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Inventory Disclosure [Abstract]    
Raw materials $ 46,659 $ 43,138
Work in process 2,954 3,481
Finished goods and parts 83,284 71,911
Total inventories $ 132,897 $ 118,530
v3.25.2
DIVESTITURE (Narrative) (Details) - Geomagic software - Disposal Group, Disposed of by Sale, Not Discontinued Operations - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2025
Apr. 01, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Sale of business in cash     $ 119.4
Pre-tax gain $ 125.7 $ 125.7  
v3.25.2
DIVESTITURE (Schedule of Components of Assets and Liabilities Held for Sale) (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Assets    
Total current assets held for sale $ 0 $ 3,176
Liabilities    
Liabilities held for sale $ 0 10,251
Geomagic software | Disposal Group, Held-for-Sale, Not Discontinued Operations    
Assets    
Accounts receivable, net   765
Prepaid expenses and other current assets   47
Total current assets held for sale   812
Intangible assets, net   917
Other assets   1,447
Total assets held for sale   3,176
Liabilities    
Accounts payable   491
Accrued and other liabilities   303
Deferred revenue   7,197
Liabilities held for sale   7,991
Other liabilities   2,260
Total liabilities held for sale   $ 10,251
v3.25.2
INVESTMENTS AND NOTE RECEIVABLE (Schedule of Equity Investments) (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]    
Equity investments under the equity method of accounting $ 3,362 $ 5,051
Equity investments without readily determinable fair values 21,712 20,696
Total equity investments $ 25,074 $ 25,747
v3.25.2
INVESTMENTS AND NOTE RECEIVABLE (Narrative) (Details)
$ in Thousands
 1 Months Ended 6 Months Ended
Feb. 28, 2025
USD ($)
Jun. 30, 2025
USD ($)
entity
Dec. 31, 2024
USD ($)
Schedule of Equity Method Investments [Line Items]      
Aggregate carrying value of equity investments without a readily determinable value   $ 21,712 $ 20,696
Number of entities | entity   3  
Maximum exposure to losses   $ 20,200  
Carrying value of investments included within expenses and other current assets   2,000  
Enhatch      
Schedule of Equity Method Investments [Line Items]      
Payments to acquire investments   $ 900  
Ownership percentage   79.00%  
Percentage of voting stock outstanding   46.00%  
GenesisTissue      
Schedule of Equity Method Investments [Line Items]      
Ownership percentage   8.00%  
Aggregate carrying value of equity investments without a readily determinable value   $ 1,000  
Saudi Arabian Industrial Investments Company      
Schedule of Equity Method Investments [Line Items]      
Amount to finance its working capital   $ 2,000 $ 2,000
Hull Legacy Media Corporation      
Schedule of Equity Method Investments [Line Items]      
Provided financing $ 1,000    
v3.25.2
BORROWINGS (Narrative) (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 23, 2025
USD ($)
$ / shares
Nov. 16, 2021
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
$ / shares
Jun. 30, 2024
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
$ / shares
Jun. 30, 2024
USD ($)
$ / shares
Jun. 17, 2025
$ / shares
Dec. 31, 2024
Line of Credit Facility [Line Items]                    
Share price (in dollars per share) | $ / shares     $ 2.60   $ 2.60 $ 4.28 $ 2.60 $ 4.28    
Amortization of debt issuance costs         $ 300 $ 300 $ 600 $ 700    
Gain on extinguishment of debt             $ 8,203 21,518    
Convertible Senior Notes Due 2030 | Convertible Debt                    
Line of Credit Facility [Line Items]                    
Aggregate principal amount $ 92,000                  
Interest rate (as a percentage) 5.875%   5.875%   5.875%   5.875%      
Cash on hand to repurchase $ 78,000                  
Debt instrument, repurchased face amount 179,700                  
Debt instrument, covenant, cash 40,000                  
Debt instrument, covenant, accounts receivable and inventory 75,000                  
Debt instrument, covenant, restricted cash $ 16,800                  
Conversion ratio 0.4456328                  
Debt instrument, conversion price (in dollars per share) | $ / shares $ 2.24                  
Premium over closing price (as a percentage) 20.00%                  
Share price (in dollars per share) | $ / shares                 $ 1.87  
Debt instrument, principal (as a percentage) 100.00%                  
Conversion price (as a percentage) 130.00%                  
Net proceeds     $ 92,000              
Gain on extinguishment of debt     8,200              
Deferred debt issuance cost, write-off     $ 1,500              
Convertible Senior Notes Due 2026 | Convertible Debt                    
Line of Credit Facility [Line Items]                    
Aggregate principal amount   $ 460,000                
Interest rate (as a percentage) 0.00%   0.00%   0.00%   0.00%     0.00%
Debt instrument, repurchased face amount       $ 110,500            
Conversion ratio   0.0278364                
Conversion price (as a percentage)   130.00%                
Effective interest rate (as a percentage)   0.594%                
Conversion price (in dollars per share) | $ / shares   $ 35.92                
Gain on extinguishment of debt               21,500    
Deferred debt issuance cost, write-off               $ 1,800    
Repayments of convertible debt       $ 87,200            
v3.25.2
BORROWINGS (Schedule of Convertible Notes Payable) (Details) - Convertible Debt - USD ($)
$ in Thousands
Jun. 30, 2025
Jun. 23, 2025
Dec. 31, 2024
Line of Credit Facility [Line Items]      
Outstanding Principal $ 126,747   $ 214,378
Unamortized Deferred Issuance Costs (4,104)   (2,383)
Carrying Amount $ 122,643   $ 211,995
Convertible Senior Notes Due 2026      
Line of Credit Facility [Line Items]      
Interest rate (as a percentage) 0.00% 0.00% 0.00%
Outstanding Principal $ 34,717   $ 214,378
Unamortized Deferred Issuance Costs (283)   (2,383)
Carrying Amount $ 34,434   211,995
Convertible Senior Notes Due 2030      
Line of Credit Facility [Line Items]      
Interest rate (as a percentage) 5.875% 5.875%  
Outstanding Principal $ 92,030    
Unamortized Deferred Issuance Costs (3,821)    
Carrying Amount $ 88,209   $ 0
v3.25.2
STOCK-BASED COMPENSATION (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Oct. 04, 2022
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Apr. 29, 2024
Dec. 01, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period       3 years      
Reversal of expense   $ 6,600          
Stock-based compensation (benefit) expense   $ (3,561) $ 5,421 $ 607 $ 13,673    
Share-Based Payment Arrangement, Tranche One              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage       33.33%      
Share-Based Payment Arrangement, Tranche Two              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage       33.33%      
Share-Based Payment Arrangement, Tranche Three              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage       33.33%      
Restricted stock and RSUs              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period   3 years          
Granted (in shares)   810          
Granted (in dollars per share)   $ 0.47          
Restricted stock and RSUs | Share-Based Payment Arrangement, Tranche One              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage       33.33%      
Restricted stock and RSUs | Share-Based Payment Arrangement, Tranche Two              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage       33.33%      
Restricted stock and RSUs | Share-Based Payment Arrangement, Tranche Three              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting percentage       33.33%      
Restricted Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period   3 years          
Granted (in shares)   1,014          
Granted (in dollars per share)   $ 2.02          
Incentive Awards              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation (benefit) expense     700   2,300    
Phantom Share Units (PSUs)              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vesting period       2 years      
Unrecognized stock-based compensation expense   $ 12,900   $ 12,900      
Dp polar GmbH              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Additional payments $ 2,200            
Issuance of shares (in shares) 250 250   250      
Volumetric Biotechnologies, Inc.              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation (benefit) expense   $ 0 $ 700 $ 0 $ 1,000    
Additional payments           $ 175,000 $ 355,000
v3.25.2
STOCK-BASED COMPENSATION (Schedule of Stock-based Compensation Expense) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]        
Stock-based compensation (benefit) expense $ (3,561) $ 5,421 $ 607 $ 13,673
v3.25.2
INCOME TAXES (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Tax Disclosure [Abstract]        
Effective income tax rate 9.40% (1.80%) 14.40% (4.60%)
v3.25.2
NET INCOME (LOSS) PER SHARE (Net Income (Loss) Per Share Reconciliation) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Oct. 04, 2022
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Numerator (basic):              
Net income (loss) attributable to 3D Systems Corporation   $ 104,436 $ (36,986) $ (27,258) $ (16,001) $ 67,450 $ (43,259)
Redeemable non-controlling interest redemption value in excess of carrying value   0   (98) $ (75) 0 (173)
Net income (loss) attributable to 3D Systems' common stock shareholders   104,436   (27,356)   67,450 (43,432)
Numerator (diluted):              
Net income (loss) attributable to 3D Systems' common stock shareholders   104,436   (27,356)   67,450 (43,432)
Add back: Interest on 2030 Notes   104   0   104 0
Net income (loss) attributable to 3D Systems' common stock shareholders plus assumed conversions   $ 104,540   $ (27,356)   $ 67,554 $ (43,432)
Denominator:              
Basic weighted average common shares outstanding (in shares)   132,280   131,802   132,370 131,311
Effect of Dilutive securities:              
Restricted stock and RSUs (in shares)   1,222   0   1,653 0
Conversion of 2030 Notes (in shares)   49,214   0   49,214 0
Diluted weighted average common shares outstanding (in shares)   182,716   131,802   183,237 131,311
Net income (loss) per common share:              
Basic (in dollars per share)   $ 0.79   $ (0.21)   $ 0.51 $ (0.33)
Diluted (in dollars per share)   $ 0.57   $ (0.21)   $ 0.37 $ (0.33)
Anti-dilutive shares (in shares)   4,075   3,553   2,929 4,489
Dp polar GmbH              
Net income (loss) per common share:              
Issuance of shares (in shares) 250 250       250  
v3.25.2
NET INCOME (LOSS) PER SHARE (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 23, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 17, 2025
Subsidiary, Sale of Stock [Line Items]            
Potentially dilutive shares that have been excluded (in shares)   4,075 3,553 2,929 4,489  
Share price (in dollars per share)   $ 2.60 $ 4.28 $ 2.60 $ 4.28  
Treasury stock, common, shares (in shares) 8,000          
Shares repurchase common stock (in dollars per share) $ 1.87          
Convertible Senior Notes Due 2030 | Convertible Debt            
Subsidiary, Sale of Stock [Line Items]            
Share price (in dollars per share)           $ 1.87
Aggregate principal amount $ 92.0          
Interest rate (as a percentage) 5.875% 5.875%   5.875%    
Incentive Awards            
Subsidiary, Sale of Stock [Line Items]            
Potentially dilutive shares that have been excluded (in shares)   0 0 146 531  
v3.25.2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Schedule of Accumulated Other Comprehensive Loss By Component) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance $ 145,639 $ 408,365 $ 176,193 $ 426,753
Other comprehensive income (loss) 9,089 (1,198) 12,141 (8,391)
Ending balance 241,246 381,729 241,246 381,729
Accumulated Other Comprehensive Loss        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance (52,014) (51,443) (55,066) (44,250)
Ending balance (42,925) (52,641) (42,925) (52,641)
Foreign currency translation adjustment        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance (52,171) (51,750) (55,217) (44,564)
Other comprehensive income (loss) 9,075 (1,196) 12,121 (8,382)
Ending balance (43,096) (52,946) (43,096) (52,946)
Defined benefit pension plan        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance 157 307 151 314
Other comprehensive income (loss) 14 (2) 20 (9)
Ending balance $ 171 $ 305 $ 171 $ 305
v3.25.2
SEGMENT INFORMATION (Narrative) (Details)
 6 Months Ended
Jun. 30, 2025
segment
Segment Reporting [Abstract]  
Number of reportable segments 2
v3.25.2
SEGMENT INFORMATION (Schedule of Operating Results by Segment) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenue:        
Revenue $ 94,838 $ 113,252 $ 189,378 $ 216,157
Cost of sales:        
Total cost of sales 58,688 66,154 120,539 128,137
Gross profit:        
Gross profit 36,150 47,098 68,839 88,020
Selling, general and administrative (34,139) (51,494) (83,908) (108,798)
Research and development (17,361) (22,016) (37,044) (45,496)
Foreign exchange gain (loss), net (1,591) (723) (452) 1,186
Interest income 1,717 1,452 2,670 4,250
Interest expense (697) (624) (1,278) (1,338)
Gain on disposition 125,681 0 125,681 0
Other income, net 7,020 384 6,860 21,770
Loss before income taxes 116,780 (25,923) 81,368 (40,406)
Operating Segments        
Revenue:        
Revenue 94,838 113,252 189,378 216,157
Cost of sales:        
Total cost of sales 58,688 66,154 120,539 128,137
Gross profit:        
Gross profit 36,150 47,098 68,839 88,020
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment        
Gross profit:        
Selling, general and administrative 34,139 51,494 83,908 108,798
Research and development 17,361 22,016 37,044 45,496
Foreign exchange gain (loss), net (1,591) (723) (452) 1,186
Interest income 1,717 1,452 2,670 4,250
Interest expense (697) (624) (1,278) (1,338)
Gain on disposition 125,681 0 125,681 0
Other income, net 7,020 384 6,860 21,770
Healthcare Solutions | Operating Segments        
Revenue:        
Revenue 45,020 48,900 86,336 94,313
Cost of sales:        
Total cost of sales 24,638 26,465 49,930 54,896
Gross profit:        
Gross profit 20,382 22,435 36,406 39,417
Industrial Solutions | Operating Segments        
Revenue:        
Revenue 49,818 64,352 103,042 121,844
Cost of sales:        
Total cost of sales 34,050 39,689 70,609 73,241
Gross profit:        
Gross profit $ 15,768 $ 24,663 $ 32,433 $ 48,603
v3.25.2
SEGMENT INFORMATION (Schedule of Depreciation and Amortization) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Healthcare Solutions        
Segment Reporting Information [Line Items]        
Depreciation and amortization $ 1,201 $ 1,365 $ 2,685 $ 2,720
Industrial Solutions        
Segment Reporting Information [Line Items]        
Depreciation and amortization $ 671 $ 782 $ 1,293 $ 1,531
v3.25.2
COMMITMENTS AND CONTINGENCIES (Narrative) (Details)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 10, 2025
day
Aug. 21, 2024
USD ($)
Apr. 29, 2024
USD ($)
employee
milestone
Mar. 29, 2024
USD ($)
Feb. 24, 2024
USD ($)
milestone
Jun. 02, 2023
USD ($)
Dec. 01, 2021
USD ($)
milestone
May 19, 2021
defendant
May 31, 2023
USD ($)
Feb. 28, 2023
USD ($)
installment
Mar. 31, 2025
USD ($)
Jun. 30, 2025
USD ($)
Loss Contingencies [Line Items]                        
Obligation to purchase inventory                       $ 19.8
Purchase obligation, to be purchase within next year                       10.3
Volumetric Biotechnologies, Inc.                        
Loss Contingencies [Line Items]                        
Payments for legal settlements   $ 1.8                    
Additional payments     $ 175.0       $ 355.0          
Number of milestones | milestone             7          
Milestones terminated | milestone         4              
Business combination, contingent consideration, reduced liability         $ 175.0              
Remaining milestones | milestone     3   3              
Acquisition related earnout amount to be recovered       $ 355.0                
Negotiation period       30 days                
Number of employees | employee     2                  
Negotiation days | day 45                      
Financial Standby Letter of Credit                        
Loss Contingencies [Line Items]                        
Guarantor obligations, maximum exposure, undiscounted           $ 1.2            
Guarantor obligations, extension term           1 year            
Letter of credit                       $ 0.8
Export Controls and Government Contracts Compliance                        
Loss Contingencies [Line Items]                        
Amount awarded                   $ 15.0    
Payments for legal settlements                     $ 3.0  
Export Controls and Government Contracts Compliance | Directorate of Defense Trade Controls                        
Loss Contingencies [Line Items]                        
Amount awarded                   $ 10.0 $ 10.0  
Number of installment payments | installment                   3    
Payment period (in years)                   3 years 3 years 3 years
Suspended penalty amount                       $ 5.1
Export Controls and Government Contracts Compliance | Bureau of Industry and Security of the Department of Commerce                        
Loss Contingencies [Line Items]                        
Amount awarded                   $ 2.8    
Export Controls and Government Contracts Compliance | U.S. Department of Justice                        
Loss Contingencies [Line Items]                        
Amount awarded                   $ 2.3    
Intrepid Automation                        
Loss Contingencies [Line Items]                        
Number of employees brought against in lawsuit | defendant               5        
Litigation amount                 $ 20.0      
v3.25.2
COMMITMENTS AND CONTINGENCIES (Schedule of Product Warranty Liability) (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Warrant Obligation [Roll Forward]    
Balance at beginning of period $ 2,650 $ 2,106
Settlements Made (1,548) (1,770)
Accruals For Warranties Issued 2,350 858
Balance at the end of period $ 3,452 $ 1,194
v3.25.2
FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - Money market funds - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 54,562 $ 98,212
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 54,562 98,212
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 0 $ 0
v3.25.2
FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Financial Instruments) (Details) - Convertible Debt - USD ($)
$ in Thousands
Jun. 30, 2025
Jun. 23, 2025
Dec. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Long-Term Debt $ 122,643   $ 211,995
Convertible Senior Notes Due 2026      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Interest rate (as a percentage) 0.00% 0.00% 0.00%
Long-Term Debt $ 34,434   $ 211,995
Fair Value $ 30,443   189,409
Convertible Senior Notes Due 2030      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Interest rate (as a percentage) 5.875% 5.875%  
Long-Term Debt $ 88,209   0
Fair Value $ 92,030   $ 0
v3.25.2
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Narrative) (Details)
$ in Millions
Jun. 30, 2025
USD ($)
Minimum  
Restructuring Cost and Reserve [Line Items]  
Expected restructuring charges $ 11
Maximum  
Restructuring Cost and Reserve [Line Items]  
Expected restructuring charges $ 20
v3.25.2
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Restructuring and Other Related Charges) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 5,145 $ 87 $ 6,142 $ 138
2025 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 5,145   6,142  
2023 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   87   138
Employee severance related        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges     6,142  
Employee severance related | 2025 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 5,145   6,142  
Employee severance related | 2023 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   (402)   (351)
Facility exit and other related | 2025 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 0   $ 0  
Facility exit and other related | 2023 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   $ 489   $ 489
v3.25.2
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Costs Incurred) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 5,145 $ 87 $ 6,142 $ 138
Cost of sales        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 838 (1,025) 1,001 (992)
Selling, general, and administrative expenses        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 3,622 873 4,180 891
Research and development        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 685 $ 239 $ 961 $ 239
v3.25.2
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Cost of Sales by Reportable Segment) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 5,145 $ 87 $ 6,142 $ 138
Cost of sales        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 838 (1,025) 1,001 (992)
Healthcare Solutions        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 458 (1,025) 512 (992)
Industrial Solutions        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 380 $ 0 $ 489 $ 0
v3.25.2
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Restructuring Charges) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Restructuring Reserve [Roll Forward]        
Beginning Balance     $ 0  
Costs Incurred $ 5,145 $ 87 6,142 $ 138
Paid/Settled     (1,962)  
Ending Balance 4,180   4,180  
Employee severance related        
Restructuring Reserve [Roll Forward]        
Beginning Balance     0  
Costs Incurred     6,142  
Paid/Settled     (1,962)  
Ending Balance $ 4,180   $ 4,180